NCT04914026 MicroRNA as Markers in Testicular Cancer
| NCT ID | NCT04914026 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Haukeland University Hospital |
| Condition | Testicular Germ Cell Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2016-12-31 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2016-12-31 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of this study is establish the performance of miR371 in management of testicular cancer
Eligibility Criteria
Inclusion Criteria: * Patients with suspected testicular cancer, referred to orchiectomy. * Patients diagnosed with testicular germ cell cancer. * Age 18-70 years of age. * Must be able receive information and to consent. Exclusion Criteria: * Other prior or concomitant malignancy (other than testicular cancer). * Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.
Contact & Investigator
Mette Pernille Myklebust, PhD
PRINCIPAL INVESTIGATOR
Haukeland University Hospital
Frequently Asked Questions
Who can join the NCT04914026 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 70 Years, studying Testicular Germ Cell Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04914026 currently recruiting?
Yes, NCT04914026 is actively recruiting participants. Contact the research team at mette.pernille.myklebust@helse-bergen.no for enrollment information.
Where is the NCT04914026 trial being conducted?
This trial is being conducted at Bergen, Norway, Haugesund, Norway, Oslo, Norway, Tromsø, Norway and 2 additional locations.
Who is sponsoring the NCT04914026 clinical trial?
NCT04914026 is sponsored by Haukeland University Hospital. The principal investigator is Mette Pernille Myklebust, PhD at Haukeland University Hospital. The trial plans to enroll 350 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.